Dose Study in Healthy Japanese Males Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083
Dose Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NCC126-0083 in Healthy Male Japanese Subjects.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Neuss, Germany, 41460
- Novo Nordisk Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy male subjects with Japanese passport and Japanese born parents
- Body Mass Index (BMI, kg/m2) between 18.0 and 27.0, both inclusive
- Subjects must be in good health according to age
Exclusion Criteria:
- A history or presence of cancer, diabetes, or any clinically significant cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological, haematological, dermatological, venereal, neurological, psychiatric diseases or other major diseases
- History of any illnesses or disease that, in the opinion of the Investigator might confound the results of the trial or pose additional risk in administering the trial product to the subject
- Any clinically significant abnormal haematology, biochemistry or urinalysis screening tests, as judged by the Investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: E
|
Dose level 1; (6 subjects active, 2 subjects placebo); s.c.
injection once weekly for 3 weeks
Dose level 2; (6 subjects active, 2 subjects placebo); s.c.
injection once weekly for 3 weeks
Dose level 3; (6 subjects active, 2 subjects placebo); s.c.
injection once weekly for 3 weeks
Dose level 4; (6 subjects active, 2 subjects placebo); s.c.
injection once weekly for 3 weeks
Dose level 1; NNC126-0083 placebo for s.c.
injection once weekly for 3 weeks
Dose level 2; NNC126-0083 placebo for s.c.
injection once weekly for 3 weeks
Dose level 3; NNC126-0083 placebo for s.c.
injection once weekly for 3 weeks
Dose level 4; NNC126-0083 placebo for s.c.
injection once weekly for 3 weeks
Dose level 3 repeated; NNC126-0083 placebo for s.c.
injection once weekly for 3 weeks
Dose level 3 repeated; NNC126-0083 placebo for s.c.
injection once weekly for 3 weeks
|
|
Experimental: A
|
Dose level 1; (6 subjects active, 2 subjects placebo); s.c.
injection once weekly for 3 weeks
Dose level 2; (6 subjects active, 2 subjects placebo); s.c.
injection once weekly for 3 weeks
Dose level 3; (6 subjects active, 2 subjects placebo); s.c.
injection once weekly for 3 weeks
Dose level 4; (6 subjects active, 2 subjects placebo); s.c.
injection once weekly for 3 weeks
Dose level 1; NNC126-0083 placebo for s.c.
injection once weekly for 3 weeks
Dose level 2; NNC126-0083 placebo for s.c.
injection once weekly for 3 weeks
Dose level 3; NNC126-0083 placebo for s.c.
injection once weekly for 3 weeks
Dose level 4; NNC126-0083 placebo for s.c.
injection once weekly for 3 weeks
Dose level 3 repeated; NNC126-0083 placebo for s.c.
injection once weekly for 3 weeks
Dose level 3 repeated; NNC126-0083 placebo for s.c.
injection once weekly for 3 weeks
|
|
Experimental: B
|
Dose level 1; (6 subjects active, 2 subjects placebo); s.c.
injection once weekly for 3 weeks
Dose level 2; (6 subjects active, 2 subjects placebo); s.c.
injection once weekly for 3 weeks
Dose level 3; (6 subjects active, 2 subjects placebo); s.c.
injection once weekly for 3 weeks
Dose level 4; (6 subjects active, 2 subjects placebo); s.c.
injection once weekly for 3 weeks
Dose level 1; NNC126-0083 placebo for s.c.
injection once weekly for 3 weeks
Dose level 2; NNC126-0083 placebo for s.c.
injection once weekly for 3 weeks
Dose level 3; NNC126-0083 placebo for s.c.
injection once weekly for 3 weeks
Dose level 4; NNC126-0083 placebo for s.c.
injection once weekly for 3 weeks
Dose level 3 repeated; NNC126-0083 placebo for s.c.
injection once weekly for 3 weeks
Dose level 3 repeated; NNC126-0083 placebo for s.c.
injection once weekly for 3 weeks
|
|
Experimental: C
|
Dose level 1; (6 subjects active, 2 subjects placebo); s.c.
injection once weekly for 3 weeks
Dose level 2; (6 subjects active, 2 subjects placebo); s.c.
injection once weekly for 3 weeks
Dose level 3; (6 subjects active, 2 subjects placebo); s.c.
injection once weekly for 3 weeks
Dose level 4; (6 subjects active, 2 subjects placebo); s.c.
injection once weekly for 3 weeks
Dose level 1; NNC126-0083 placebo for s.c.
injection once weekly for 3 weeks
Dose level 2; NNC126-0083 placebo for s.c.
injection once weekly for 3 weeks
Dose level 3; NNC126-0083 placebo for s.c.
injection once weekly for 3 weeks
Dose level 4; NNC126-0083 placebo for s.c.
injection once weekly for 3 weeks
Dose level 3 repeated; NNC126-0083 placebo for s.c.
injection once weekly for 3 weeks
Dose level 3 repeated; NNC126-0083 placebo for s.c.
injection once weekly for 3 weeks
|
|
Experimental: D
|
Dose level 1; (6 subjects active, 2 subjects placebo); s.c.
injection once weekly for 3 weeks
Dose level 2; (6 subjects active, 2 subjects placebo); s.c.
injection once weekly for 3 weeks
Dose level 3; (6 subjects active, 2 subjects placebo); s.c.
injection once weekly for 3 weeks
Dose level 4; (6 subjects active, 2 subjects placebo); s.c.
injection once weekly for 3 weeks
Dose level 1; NNC126-0083 placebo for s.c.
injection once weekly for 3 weeks
Dose level 2; NNC126-0083 placebo for s.c.
injection once weekly for 3 weeks
Dose level 3; NNC126-0083 placebo for s.c.
injection once weekly for 3 weeks
Dose level 4; NNC126-0083 placebo for s.c.
injection once weekly for 3 weeks
Dose level 3 repeated; NNC126-0083 placebo for s.c.
injection once weekly for 3 weeks
Dose level 3 repeated; NNC126-0083 placebo for s.c.
injection once weekly for 3 weeks
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Safety and tolerability (adverse events, local tolerability, physical examination)
Time Frame: 0 to 10 days after third dosing, (day 15-25 after first dose)
|
0 to 10 days after third dosing, (day 15-25 after first dose)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Cmax, maximum concentration of IGF-I
Time Frame: 7 days after first dosing and 10 days after the third dosing (day 1-25 after first dose)
|
7 days after first dosing and 10 days after the third dosing (day 1-25 after first dose)
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- NN8630-1958
- 2008-001578-33 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.